Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

Blood (2024) 143 (13): 1259–1268.

https://doi.org/10.1182/blood.2023022399

Published: 2024

Includes: Supplemental data

Journal Articles

The UK Experience of Renal Transplantation in AL Amyloidosis

Oliver C Cohen, MB BS, BSc, FRCPath, Faye Sharpley, MBBChir, MA, MRCP, MSc, Julian Gillmore, Helen Lachmann, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Ana Martinez De Azcona Naharro, Marianna Fontana, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (Supplement_1): 2206.

https://doi.org/10.1182/blood-2019-128443

Published: 2019

Journal Articles

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Richa Manwani, MBBS, FRCPath, BSc, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2018-99-116688

Published: 2018

Journal Articles

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Faye Sharpley, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 4445.

https://doi.org/10.1182/blood-2018-99-114028

Published: 2018

Journal Articles

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Blood (2017) 130 (Supplement 1): 1815.

https://doi.org/10.1182/blood.V130.Suppl_1.1815.1815

Published: 2017

Journal Articles

Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study

Richa Manwani, MBBS, FRCPath, BSc, Darren Foard, Shameem Mahmood, Sajitha Sachchithanantham, BSc,FRCPath,MBBS,MRCP, Marianna Fontana, Carol Whelan, Candida Quarta, Thirusha Lane, Helen Lachmann, Julian Gillmore, Philip Hawkins, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2017) 130 (Supplement 1): 1816.

https://doi.org/10.1182/blood.V130.Suppl_1.1816.1816

Published: 2017

Journal Articles

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

Ashutosh Wechalekar, MD FRCPath, Darren Foard, Carol Whelan, MD FRCP, Mariana Fontana, Thirusha Lane, RN MSc, Candida Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MD FRCP, Julian D Gillmore, MD PhD FRCP, Philip N Hawkins, MD PhD FMedSci

Blood (2016) 128 (22): 4511.

https://doi.org/10.1182/blood.V128.22.4511.4511

Published: 2016

Journal Articles

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Belen Sevillano, Haematology Specialist, Ashutosh Wechalekar, MDFRCPath FRCP, Darren Foard, Specialist Nurse, Carol Whelan, MDFRCP, Marianna Fontana, MD, Cristina Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MDFRCP, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 5357.

https://doi.org/10.1182/blood.V126.23.5357.5357

Published: 2015

Journal Articles

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MDFRCP, Helen Lachmann, MDFRCP, Marianna Fontana, MD, Shameem Mahmood, FRCPath, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 732.

https://doi.org/10.1182/blood.V126.23.732.732

Published: 2015

Journal Articles

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

Giovanni Palladini, Sajitha Sachchithanantham, Paolo Milani, Julian Gillmore, Andrea Foli, Helen Lachmann, Marco Basset, Philip Hawkins, Giampaolo Merlini, Ashutosh D. Wechalekar

Blood (2015) 126 (5): 612–615.

https://doi.org/10.1182/blood-2015-01-620302

Published: 2015

Includes: Supplemental data

Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 1981.

https://doi.org/10.1182/blood.V122.21.1981.1981

Published: 2013

Journal Articles

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, MRCP, FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3120.

https://doi.org/10.1182/blood.V122.21.3120.3120

Published: 2013

Journal Articles

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Christopher P Venner, MD, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Shameem Mahmood, MBBCh. FRCPath, Simon DJ Gibbs, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD

Blood (2012) 120 (21): 2966.

https://doi.org/10.1182/blood.V120.21.2966.2966

Published: 2012

Journal Articles

ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis

Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Ashutosh Wechalekar, MD, Simon Gibbs, MD, Jennifer Pinney, MD, Christopher P Venner, MD, Sanjay Banypersad, MD, Helen Lachmann, MD, Philip N Hawkins, MD, Julian D Gillmore, MD

Blood (2011) 118 (21): 992.

https://doi.org/10.1182/blood.V118.21.992.992

Published: 2011

Journal Articles

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Christopher P. Venner, MD, Julian D Gillmore, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Simon DJ Gibbs, Jennifer Pinney, MD, Carol Whelan, Helen Lachmann, MD, Philip N Hawkins, Ashutosh Wechalekar, MD

Blood (2011) 118 (21): 3975.

https://doi.org/10.1182/blood.V118.21.3975.3975

Published: 2011

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

Blood (2011) 118 (21): 3978.

https://doi.org/10.1182/blood.V118.21.3978.3978

Published: 2011

Journal Articles

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial.

Julian Gillmore, Kim Cocks, Simon DJ Gibbs, Prayman T Sattianayagam, Thirusha Lane, Helen Lachmann, Stephen Schey, James D. Cavenagh, Heather Oakervee, Gareth J Morgan, Atul B Mehta, Suzan Bourne, E. Skinner, G. Booth, Philip N Hawkins, Ashutosh D Wechalekar

Blood (2009) 114 (22): 2869.

https://doi.org/10.1182/blood.V114.22.2869.2869

Published: 2009

Journal Articles

Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.

Marna de Cruz, Babita Pawarova, Helen Lachmann, Julian Gillmore, Simon Gibbs, Prayman Sattianayagam, Philip Hawkins, Ashutosh D Wechalekar

Blood (2009) 114 (22): 2814.

https://doi.org/10.1182/blood.V114.22.2814.2814

Published: 2009

Journal Articles

A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.

Ashutosh D Wechalekar, Nancy L Wassef, Simon DJ Gibbs, Julian Gillmore, Felicia Dike, Helen Lachmann, Prayman Sattianayagam, Arthur Bradwell, Philip N Hawkins

Blood (2009) 114 (22): 2796.

https://doi.org/10.1182/blood.V114.22.2796.2796

Published: 2009

Journal Articles

Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.

Ashutosh Wechalekar, Julian Gillmore, Helen Lachmann, Mark Offer, Philip Hawkins

Blood (2006) 108 (11): 129.

https://doi.org/10.1182/blood.V108.11.129.129

Published: 2006

NARROW

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

The UK Experience of Renal Transplantation in AL Amyloidosis

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial.

Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.

A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.

Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only